US Congress Proposes Disposable ENDS Product Enforcement Act

Mar.14.2023
US Congress Proposes Disposable ENDS Product Enforcement Act
The Disposable ENDS Product Enforcement Act of 2023 aims to regulate and prioritize enforcement measures against disposable e-cigarettes.

On March 13th, it was reported that the full text of the proposal for the "Disposable ENDS Product Enforcement Act of 2023" has been made public on the official website of the United States Congress. The bill was introduced by Sheila Cherfilus McCormick, a member of the House of Representatives from Florida, and has been assigned to the House Energy and Commerce Committee.


Hillary Schefter-McCormick | Source: Official website of the United States Congress


The bill cites a study released by the U.S. Food and Drug Administration in 2022 that indicates disposable e-cigarettes are the most commonly used type of device among underage individuals in the United States.


Based on this premise, the bill requires that within 90 days of its passage, the Department of Health and Human Services (HHS) must update its enforcement priorities for electronic nicotine delivery systems (ENDS) and other deemed products that have not been authorized for pre-market sale, as outlined in its April 2020 publication. The updated regulations must include measures on how to prioritize enforcement actions against disposable ENDS products, including non-tobacco derived nicotine products.


According to reports, as of March 10, there are four co-sponsors of the bill, all of whom are Democratic members of the House of Representatives, as listed on Congress's website. The House is majority-controlled by Republicans, with 222 seats, while Democrats hold 213 seats. Previously, Republican Kevin McCarthy faced opposition from far-right conservative members before ultimately winning the election as Speaker of the House after 15 rounds of voting, marking the most rounds of voting in a House Speaker election since 1923.


References:


HR901 - One-time Enforcement of ENDS Products Act in 2023.


Additional reading:


A new US bill is pressuring the FDA to crack down on disposable e-cigarettes.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE® Nicotine Pouches announced a partnership with Taylor Reimer Racing, becoming the Official Nicotine Sponsor for four races in the 2026 ARCA Menards Series and serving as the primary sponsor at events in Alabama, Michigan, Minnesota, and Arizona. FRE branding will appear on the race car, driver suit, and helmet, and the collaboration will also extend to off-track content and activations.
Feb.27
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products
Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products
South Korea’s Ministry of Food and Drug Safety (MFDS) said it has established its 2026 work plan to systematically manage harmful constituents in tobacco products and disclose related information under the Tobacco Harmfulness Management Act, which took effect in November 2025.
Jan.16 by 2FIRSTS.ai
Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group (STG) reported its 2025 results: revenue was 9.036 billion Danish kroner (about $1.407 billion); EBITDA before special items was 1.791 billion Danish kroner (about $278 million); and free cash flow before acquisitions was 595 million Danish kroner (about $92.7 million). Multiple metrics declined year over year, and the company did not meet its Q3-updated guidance for revenue and free cash flow.
Mar.05 by 2FIRSTS.ai